Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | XBP1 | P17861 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9407584 | 0.86 | HDAC1 (0.41) | MAOBHDAC1HDAC2MAPTMEN1 | |
| SCHEMBL22319227 | 0.84 | FABP7 (0.45) | FABP7MAOBHDAC1HDAC2MAPT | |
| SCHEMBL575458 | 0.81 | ATM (0.41) | MAPTHTTGAAMEN1KMT2A | |
| SCHEMBL15853317 | 0.81 | L3MBTL1 (0.49) | MAPTATML3MBTL1ELANETDP1 | |
| SCHEMBL9244671 | 0.81 | MAOB (0.55) | FABP7MAOBMAPTHTTGAA | |
| SCHEMBL9244660 | 0.81 | MAOB (0.55) | FABP7MAOBMAPTHTTGAA | |
| SCHEMBL322125 | 0.80 | MAPT (0.44) | HDAC1HDAC2MAPTHTTMEN1 | |
| SCHEMBL13599585 | 0.80 | MAPK1 (0.46) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL19320324 | 0.79 | FABP7 (0.41) | FABP7MAPTHTTGAAXBP1 | |
| SCHEMBL10025073 | 0.78 | MAPT (0.46) | MAPTHTTMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| WO-2023179324-A1 | ELECTROLYTIC SOLUTION CONTAINING FLUOROBENZENE CARBONATE, AND BATTERY COMPOSED OF ELECTROLYTIC SOLUTION | 香河昆仑新能源材料股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-20220238909-A1 | SECONDARY LITHIUM-ION BATTERY ELECTROLYTE SOLUTION FOR REDUCING BATTERY RESISTANCE AND SECONDARY LITHIUM-ION BATTERY THEREOF | GUANGZHOU TINCI MATERIALS TECHNOLOGY CO., LTD. (CN) | 2022-07-28 | — | — | US | disclosed |
| US-11367899-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-3972024-A1 | SECONDARY LITHIUM-ION BATTERY ELECTROLYTE FOR REDUCING BATTERY RESISTANCE AND SECONDARY LITHIUM-ION BATTERY THEREOF | Guangzhou Tinci Materials Technology Co., Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| CN-109843892-B | Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections | 诺维拉治疗公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20210384554-A1 | LITHIUM SECONDARY BATTERY ELECTROLYTE FOR REDUCING INTERNAL RESISTANCE OF BATTERY AND LITHIUM SECONDARY BATTERY | GUANGZHOU TINCI MATERIALS TECHNOLOGY CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20100119956-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100099031-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2166611-A1 | NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| CN-101652894-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | MITSUBISHI CHEM CORP JP | 2010-02-17 | — | — | CN | disclosed |
| EP-2144321-A1 | NONAQUEOUS ELECTROLYTE FOR RECHARGEABLE BATTERY, AND RECHARGEABLE BATTERY WITH NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-20090286155-A1 | LITHIUM DIFLUOROPHOSPHATE, ELECTROLYTE CONTAINING LITHIUM DIFLUOROPHOSPHATE, PROCESS FOR PRODUCING LITHIUM DIFLUOROPHOSPHATE, PROCESS FOR PRODUCING NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY CONTAINING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2061115-A1 | LITHIUM DIFLUOROPHOSPHATE, ELECTROLYTIC SOLUTION CONTAINING LITHIUM DIFLUOROPHOSPHATE, PROCESS FOR PRODUCING LITHIUM DIFLUOROPHOSPHATE, PROCESS FOR PRODUCING NONAQUEOUS ELECTROLYTIC SOLUTION, NONAQUEOUS ELECTROLYTIC SOLUTION, AND NONAQUEOUS-ELECTROLYTIC-SOLUTION SECONDARY CELL EMPLOYING THE SAME | Mitsubishi Chemical Corporation (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | SLC9A1, NHERF1, CA2 | FABP7 4878/4885MAOB 4501/4885HDAC1 524/4885 |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | FABP7 3201/4885MAOB 170/4885HDAC1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.